Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6316169 | 0.91 | POLB (0.34) | ST6GAL1POLB | |
| SCHEMBL5396749 | 0.91 | POLB (0.31) | ST6GAL1POLB | |
| SCHEMBL6730011 | 0.89 | POLB (0.30) | POLB | |
| SCHEMBL6234928 | 0.87 | ST6GAL1 (0.35) | ST6GAL1 | |
| SCHEMBL6230190 | 0.85 | TRDMT1 (0.34) | — | |
| SCHEMBL6574062 | 0.84 | — | — | |
| SCHEMBL6236139 | 0.83 | POLB (0.36) | ST6GAL1POLB | |
| SCHEMBL5200194 | 0.82 | POLB (0.37) | ST6GAL1POLB | |
| SCHEMBL7037015 | 0.80 | POLB (0.46) | POLB | |
| SCHEMBL5200171 | 0.79 | POLB (0.40) | ST6GAL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0948514-B1 | METHOD FOR THE SYNTHESIS OF NUCLEOTIDE OR OLIGONUCLEOTIDE PHOSPHORAMIDITES | ISIS PHARMACEUTICALS INC (US) | 2005-04-27 | — | — | EP | disclosed |
| US-6870039-B2 | Synthesis of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040063925-A1 | Synthesis of oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2004-04-01 | — | — | US | disclosed |
| US-6458941-B1 | RECOVERED FROM WASTE PRODUCTS OF OLIGONUCLEOTIDE BIOSYNTHESIS | ISIS PHARMACEUTICALS, INC. | 2002-10-01 | — | — | US | disclosed |
| US-6441150-B1 | GENETIC ENGINEERING | ISIS PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
| US-6294664-B1 | PREPARING OLIGONUCLEOTIDE BLOCKS HAVING COMMON SUBSEQUENCES, PHOSPITYLATING, AND PERFORMING SOLID PHASE SYNTHESIS (SPS) TO FORM TARGET OLIGONUCLEOTIDES WHEREIN THE SYNTHONS USED IN SPS COMPRISE PHOSPHITYLATED OLIGONUCLEOTIDE BLOCKS | ISIS PHARMACEUTICALS, INC. | 2001-09-25 | — | — | US | disclosed |
| US-6211350-B1 | REACTING SYNTHON WITH TWO NUCLEOSIDE UNITS AND WITH SYNTHON HAVING ONE NUCLEOSIDE UNIT TO OBTAIN OLIGONUCLEOTIDE CONTAINING PHOSPHOROTHIOATE GROUPS | ISIS PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063925-A1 | Synthesis of oligonucleotides | RNGTT, POLRMT, POLI | ST6GAL1 2477/4885POLB 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.